

Meeting of the *London Cancer* Rehabilitation Expert Reference Group

Date: **Tuesday 1st May 2018, 15:00 -16:30**

Venue: **Ground Floor Central Meeting Room, 250 Euston Road, NW1 2PG**

Chair: **Sharon Cavanagh ERG Chair**

1. Introductions, Apologies and review minutes from last meeting

SC welcomed members of the ERG and introductions were made. Dan Joyce introduced self as new carer representative

2. Minutes from previous meeting

SC read out apologies. The action log was checked from the last meeting and minutes of the last meeting were accepted.

3. UCLH Cancer Collaborative update (SC)

In March 2018, NHSEs new care models programme finished and with it the National Cancer Vanguard (formed by Greater Manchester Cancer, RM Partners and UCLH CC). Moving forward UCLH Cancer Collaborative will continue as the Cancer Alliance for NCEL. Our priorities for 2018/19 remain the same – improve the outcomes and experience for all people with cancer or at risk of cancer.

Our New Programme Director, Naser Turabi, to commence in mid-May.

UCLH CC annual event to be held on 26 June. Details re. booking onto this to be circulated.

ACTION:

- SC to circulate Eventbrite details for the UCLH CC annual event

4. Alliance update and transformation funding (SC)

NHSE to release 85% of transformation funding to London for LWBC. A request was made to the alliances to prioritise our pan-London plan based on this revised budget.

The pan-London LWBC prioritisation form was submitted to the national team for their deadline of 23rd March, having been approved by the London regional team and relevant constituent STPs. We have received feedback from the national team and the funding agreement is in the process of being developed for alliance to sign.

5. TCST Rehabilitation Update (KR)

Benchmarking tool: Feedback has now been received from steering community, steering group, physio group in Dublin. Two services have piloted thus far. Can be completed in 30 minutes. NHSI have also reviewed and are keen to look at possibility of scaling up to other conditions.

Scoring: The aim is that teams will be benchmarking against self initially.

AHP Minimum dataset: KR has held meetings with both NHSI and NHSE re. the content. It's now in a NHS Digital format. The aim is that it will be presented at CCB for ratification in October.

Lymphoedema: The national lymphoedema partnership group is to utilise the commissioning guidance moving forward. Pan-London lymphoedema community of practice being explored. Aims of the community - to pull together the lymphoedema community to update on strategic challenges in London, facilitate networking, to review the TCST guidance. A Macmillan group grant to fund the inaugural community of practice meeting has been successful.

ACTION:

- Rehabilitation ERG members to provide feedback on the benchmarking tool to KR

6. Rehabilitation plan (SC)

Progress against objective discussed.

1) Embedding physical activity into cancer pathways

- Call for physical activity patient information has been sent to all trusts

Review of innovative practices in other local/national sites

2) Embedding rehabilitation into cancer pathways –

- Presented rehabilitation priorities to CCB

Produced paper outlining priorities and recommendations – Cancer transformation has been released therefore recruitment to an alliance Rehabilitation Project Manager to commence.

3) Consequences of Treatment – Improve Access to Services

- Mapping of *London Cancer* Lymphoedema services conducted
- Breast Lymphoedema audit conducted to determine numbers of individuals presenting with lymphoedema symptoms, severity of symptoms at first presentation and information regarding referral pathways. This is first step in a multi-tumour audit. This information will assist us to improve patient experience and outcomes by identifying any gaps in lymphoedema service provision or informing us where pressures exist on current lymphoedema services within our *London Cancer* footprint
- Current audits: melanoma. Closed May 2018
Next steps. Head and neck audit

Focus for 2018/19: Pre-habilitation, AHP mapping and development of STP level. Discussions re. approach to establish adequate baseline for benchmarking.

7. Neuro-oncology Service at Barts (All)

Description of service: Service runs 5 days a week – and patients seen twice a day by OT/PT.

Early results: Between July to December 2017, 25 patients received intervention. Evaluation methods: FIM/FAM and length of stay (LOS) to determine cost savings in acute and community sector. Total LOS: 52 days saved. Financial savings equate to £66k per month.

Results to be presented to the Barts Cancer Board.

Recommendations: EQ5D being considered as a QoL tool.

8. Service Update (All)

UCLH Lymphoedema: (CM)

One of the Clinical Nurse Specialists on the team will be leaving on a year-long career break. Discussions currently occurring regarding cover for this role.

Barts Health (LF) Neuro oncology project continuing. Outpatient provision being reviewed – with aim to expand service into Whips X in the summer.

TCST (KR)

Georgina Wiley, Macmillan Project Facilitator at TCST is moving to the Macmillan Treatment and Recovery Team so her post will be available

Next Meeting: Thursday 5th July 2018 15:00-16:30- 250 Euston Road, Ground Floor Central Meeting Room, London, NW1 2PG.

ACTION LOG

Action	Owner	Date Agreed	Status
SC to circulate Eventbrite details for the UCLH CC annual event	SC	01.05.18	
Rehabilitation ERG members to provide feedback on the benchmarking tool to KR	All	01.05.18	

Attendees

Name	Role	Trust/Organisation
Sharon Cavanagh (SC)	Living With and Beyond Cancer and AHP Lead	London Cancer/UCLH
Karen Robb (KR)	Macmillan Rehabilitation Lead	TCST
Lindsay Farthing (LF)	Clinical Lead for Oncology Therapies	Barts
Dan Joyce (DJ)	Carer representative	

Name	Role	Trust/Organisation
Christina Moore (CM)	Clinical Nurse Specialist - Lymphoedema	UCLH

Apologies

Name	Role	Trust/Organisation
Louise Platt	Therapy Team Lead Neurosurgery	NHNN

The UCLH Cancer Collaborative is a part of the national Cancer Vanguard, working with Greater Manchester Cancer Vanguard Innovation and RM Partners